A new FDA approved rituximab biosimilar has been launched in the US for its use in rheumatoid arthritis (RA) therapeutic option in combination with methotrexate. It has been found effective in adults with moderate to severe active RA who was otherwise ineffective to one or more tumor necrosis factor antagonist treatments. 

The adults with granulomatosis with polyangiitis and microscopic polyangiitis could also benefit from this biosimilar, if used in combination with glucocorticoids. Beside these indications, it has been approved in 2019 for Non-Hodgkin lymphoma, chronic lymphocytic leukemia.

According to its manufacturing company, the list price for this biosimilar will be 10% lesser as compared to the reference product.